P-40 Cisplatin and vinorelbine chemotherapy for stage IIIB and IV non-small cell lung cancer: an experience from a Chest Diseases Hospital in Turkey

Abstract

Purpose: to evaluate the efficacy of cisplatin (CDDP) vinorelbine (VNR) regimen in chemonaive patients with stage IlIE IV nonsmall cell lung cancer (NSCLC). Patients and Methods: From April 2000 to December 2001, 63 patients with advanced NSCLC were included in the study. Fifty nine patients were male and 4 female, median age was 57 years (37-76) ECOG performans status (PS) O/l was 40/23, stage IIIB/IV was 27/36. Histologic diagnosis was squamous cell lung cancer in 30 patients, adenocarcinoma in 22 and undifferentiated NSCLC in 11. Two patients had curative radiotherapy (RT) before chemotherapy (ChT). None of the patients had curative RT after ChT where as 15 had palliative RT for brain, bone metastases and pain relief. Treatment consisted of 30 mg/ms VNR on days I,8 and 70 mg/ms CDDP on day 1 of every 3 weeks. Results: All patients were evaluated for time to progression and overall response rate and toxicity. Twenty three patients received second line ChT after progression, 7 of them received it within the first year. Fifty four patients were followed up for 1 year. Two patients were lost after progression and couldn’t be reached for further treatment. A total of 320 cycles ChT were administered, 36 patients have completed 6 cycles. The overall response rate was 49% with 1 CR, 30 PR, 20 SD and 12 PD. Median follow up was 48 weeks, median time to progression 34 weeks, median survival time 48 weeks. One year survival was 51%. There was no Gr IV toxicity, 4 Gr Ill anemia (6.3%), 4 Gr Ill neutropenia (6.3%) 5 Gr Ill vomiting (7.9%). Conclusion: Cisplatin Vinorelbine combination is an effective and well tolerated regimen in the treatment of advanced NSCLC patients.